UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): October 1, 2014

 

SPHERIX INCORPORATED

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-5576   52-0849320

(State or other jurisdiction

of incorporation)

  (Commission File Number)   (IRS Employer Identification No.)

 

6430 Rockledge Drive, Suite 503

Bethesda, MD

      20817
(Address of principal executive
offices)
      (Zip Code)

 

Registrant’s telephone number, including area code: (703) 992-9260

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

  

ITEM 8.01 OTHER EVENTS

  

On October 1, 2014, Spherix Incorporated issued the press release attached hereto as Exhibit 99.1.

 

ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS

 

(d)           Exhibits.

 

The exhibit listed in the following Exhibit Index is furnished as part of this Current Report on Form 8-K.

 

Exhibit No.   Description
     
99.1   Press Release dated October 1, 2014

  

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  October 1, 2014

 

    SPHERIX INCORPORATED
     
  By:  /s/  Anthony Hayes
    Name:  Anthony Hayes
    Title:  Chief Executive Officer
     

 

 

 

 

 

 



Exhibit 99.1

 

Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014

 

- Efforts to Monetize Patent Portfolio Continue to Move Forward -

 

BETHESDA, MD, October 1, 2014 /PRNewswire/ — Spherix Incorporated (Nasdaq: SPEX) — an intellectual property development company committed to the fostering and monetization of intellectual property, announced today that the Markman hearing for Spherix’s litigation against VTech and Uniden in the U.S. District Court for the Northern District of Texas has been rescheduled for November 10, 2014. This hearing was originally scheduled for October 2, 2014. The Court Order setting the Markman date was received after the close of business on September 29, 2014. As previously indicated, all litigation dates are subject to change at any time.

 

Anthony Hayes, Chief Executive Officer of Spherix, stated, “changes to the litigation schedule are often altered, based on requests from the court or from the parties. It’s a normal part of the litigation cycle.”

 

Mr. Hayes continued, “Each case is unique, and there can be no assurances in this case, but Markman hearings typically represent an inflection point in the litigation. While this process can still take a few months to resolve, normally a Markman hearing can give the parties an understanding of how key terms will be construed. It therefore provides each side some guidance. The timing of the ruling by the Court after the Markman hearing is issued at the Court’s discretion.”

 

About Spherix

 

Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

 
 

  

Contact:

 

Investor Relations: Hayden IR
  Brett Mass, Managing Partner
  Phone: (646) 536-7331
  Email: brett@haydenir.com
  www.haydenir.com
   
Spherix: Phone: (703) 992-9325
  Email: info@spherix.com
  www.spherix.com

 

 

 

 

Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alkido Pharma Charts.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alkido Pharma Charts.